Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation

Naschla Gasaly¹, Paul de Vos² and Marcela A. Hermoso¹,³*

¹ Laboratory of Innate Immunity, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile, ² Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, ³ Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile, Santiago, Chile

The diverse and dynamic microbial community of the human gastrointestinal tract plays a vital role in health, with gut microbiota supporting the development and function of the gut immune barrier. Crosstalk between microbiota-gut epithelium and the gut immune system determine the individual health status, and any crosstalk disturbance may lead to chronic intestinal conditions, such as inflammatory bowel diseases (IBD) and celiac disease. Microbiota-derived metabolites are crucial mediators of host-microbial interactions. Some beneficially affect host physiology such as short-chain fatty acids (SCFAs) and secondary bile acids. Also, tryptophan catabolites determine immune responses, such as through binding to the aryl hydrocarbon receptor (AhR). AhR is abundantly present at mucosal surfaces and when activated enhances intestinal epithelial barrier function as well as regulatory immune responses. Exogenous diet-derived indoles (tryptophan) are a major source of endogenous AhR ligand precursors and together with SCFAs and secondary bile acids regulate inflammation by lowering stress in epithelium and gut immunity, and in IBD, AhR expression is downregulated together with tryptophan metabolites. Here, we present an overview of host microbiota-epithelium-gut immunity crosstalk and review how microbial-derived metabolites contribute to host immune homeostasis. Also, we discuss the therapeutic potential of bacterial catabolites for IBD and celiac disease and how essential dietary components such as dietary fibers and bacterial tryptophan catabolites may contribute to intestinal and systemic homeostasis.

Keywords: bacterial metabolites, gut immune barrier, inflammation, gut microbiota, dietary fiber, tryptophan, SCFAs, secondary bile acids
INTRODUCTION

A wide range of inflammatory conditions has increased steeply in Western and developing countries, attributed to changes in the mucosal immune system, specifically the gastrointestinal tract. The mucosal immune system acts as a guardian, preventing invasions and preserving a healthy gut microbiota (GM). Additionally, GM is a determining factor in general health, releasing metabolites with anti-inflammatory properties that use intestinal homeostasis. Immune responses against microbial and dietary antigens can cause inflammatory disorders such as inflammatory bowel disease (IBD) and celiac disease (1).

Particularly, IBD is a recurrent, chronic and non-specific inflammatory bowel condition that includes ulcerative colitis (UC) and Crohn’s disease (CD), disorders characterized by intermittent periods of activity (mild, moderate, or severe) or inactivity (remission). IB youngest as an abnormal immune response and chronic intestinal inflammation caused by genetic and environmental factors, in addition to complex interactions between the GM and the host’s immune system, with development of specific treatments a challenging task (2). Alternatively, celiac disease is an autoimmune destruction of the villi of the small intestine triggered by gluten in genetically susceptible individuals, causing nutrient malabsorption, leading to intestinal and extra-intestinal symptoms, and a gluten-free diet (GFD) for life the only treatment. The pathogenesis is multifactorial, and although genetic predisposition occurs in 30% - 40% of the general population, only a small proportion of these individuals will develop the disease, suggesting the importance of environmental factors, with recent evidence supporting the participation of GM (3).

Therefore, this dynamic triad in the gut (mucosal immunity, GM, and diet) can be jointly explored, modulated, and enhanced for the prevention and treatment of many inflammatory diseases.

Here, we present an overview of current knowledge on host microbiota-epithelium-gut immunity crosstalk, focusing on how microbial-derived metabolites contribute to host immune homeostasis. Also, we discuss the therapeutic potential of bacterial catabolites for some inflammatory conditions, such as IBD and celiac disease and how essential dietary components, such as dietary fibers and bacterial tryptophan catabolites aid intestinal and systemic homeostasis.

A BRIEF DESCRIPTION OF GUT MICROBIOTA AND HOST IMMUNITY

GM corresponds to microorganisms (bacteria, archaea, fungi, viruses and phages) inhabiting the human gastrointestinal tract (4). The phylum Bacteroidetes and Firmicutes represent more than 90% of the GM bacterial component, including sub-dominant phyla such as Proteobacteria, Actinobacteria and Verrucomicrobia (5, 6). Complex GM interaction with the host immune system begins at birth, where microorganisms initiate immune development and the immune system subsequently orchestrates the GM composition (7, 8). This is a vulnerable period as the intestine is a critical site for multiple host-microbe interactions during life. Commensal microorganisms establish a relationship with the host, essential for immune system development and function through production of several types of metabolites. Next to producing metabolites the GM interacts with intestinal cells in the local environment which subsequently also impacts immune homeostasis (9). This interaction with epithelium also initiates production of numerous microbial metabolites (10) and stimulate signaling pathways, profoundly impacting gut health and also that of more distal organs (11).

Gut health is highly influenced by diet. Molecular structures in diet provide substrates for the host and GM, regulating GM composition and therewith gut-immune barrier function. However, how diet influence this also depends on other factors such as genetics and lifestyle (6). Via GM and diet-derived microbial metabolites diet can influence intestinal homeostasis (12), with emerging evidence showing diet and nutrients impact GM composition, production of microbial metabolites, and immune function; and that disturbances in nutrition may result in development of intestinal diseases such as IBD (13, 14).

The realization that GM and its metabolites have a strong influence on disease development also led to the realization that GM is an attractive target to prevent disease. The microbiome constitutes a collection of aggregated genomes and genes present in GM, modulating the host’s metabolism, influencing immune system performance, and thus altering our concepts of health, disease risk, and effect of western lifestyle (4). The host-GM interactions aim to establish immune tolerance while at the same time initiating strong defense responses toward dangerous microorganisms (15). The epithelium separates the intestinal lumen from underlying tissues, with a dense layer of mucus (16). This mucosal barrier organizes around hyperglycosylated mucin MUC2, protecting and limiting the immunogenicity of intestinal antigens, determining an anti-inflammatory state in mucosa embedded dendritic cells (17). Critical for transepithelial permeability are tight junctions (TJs) that restrict passage into the host of pathogens, microbes or toxins (18). GM metabolic signals, such as indole metabolites and short chain fatty acids (SCFAs) can strengthen the epithelial barrier by increasing expression of TJs and cytoskeleton-associated proteins (19). The importance of GM for epithelial integrity is illustrated in studies showing that GM alterations (dysbiosis) and intestinal barrier function disruption trigger a wide range of pathologies, including autoimmune, neurodegenerative and inflammatory disorders (13).

Additionally, the combination of genetic, environmental and dysbiosis factors favor the development of immune response alterations, promoting inflammatory diseases (20, 21). As described, immune signals generated by GM modulate commensal microorganisms (22, 23), protecting the host against opportunistic pathogens (23). Essentially, the host-GM interactions are mediated by certain endogenous, dietary compounds and dietary-derived bacterial metabolites, mainly stimulating B cells differentiation in order to produce immunoglobulin A (IgA), initiating formation of regulatory T
cells (Treg), T helper 1 (Th1), T helper 17 (Th17), as well as group 3 innate lymphoid cells (ILC3s), among others, potentially preventing or developing inflammatory diseases (Figure 1).

DIRECT OR INDIRECT MECHANISMS OF DIETARY FIBERS AND BACTERIAL CATABOLITES AND THEIR ROLE IN HEALTH AND DISEASE

SCFAs and Health Effects

Dietary Fiber Catabolism

Dietary fiber (DF) are edible parts of plants or carbohydrates resisting digestion in the human small intestine, being partially or completely fermented by GM in the large intestine. The Codex Alimentarius defines DF as polymers of edible carbohydrates from natural sources such as cereals, fruits and vegetables, and those from raw materials by physical, enzymatic and chemical mechanisms or synthetic carbohydrate polymers with physiological benefits (24). Moreover, fermentation is influenced by many structural and physicochemical parameters. DF fermentation is associated with lower colonic pH, increased large intestinal bacterial mass, reduction of pathogens, stimulation of antioxidiant compound and vitamin production, as well as regulation of epithelial barrier and immune system stimulation, among others.

One main DF classification refers to its solubility, with secondary physiological benefits on viscosity and fermentability, contributing to gel formation in the intestinal tract, and DF metabolized by GM, respectively (25). Insoluble DFs, such as lignin and cellulose, are poorly fermentable by GM, due to their inability to retain water. Soluble DFs, such as pectin, inulin, β-glucans, oligosaccharides, and guar gum are fermentable and constitute the main energy source for GM, and generally, are more fermentable with higher viscosity (26). Fermentation is possible in the presence of keystone species and strains possessing the enzymatic capacity to metabolize specific DF (24).

Interestingly, DF fermentation changes GM diversity, depending on the DF nature (27, 28), allowing production of SCFAs, amines, ammonium, gases, and phenols. Also it stimulates growth and diversity of GM and induces release of energy and water (29). A rich saturated fat and simple carbohydrate diet, but low in DF, is associated with increased risk for obesity, diabetes, cardiovascular disease, and colorectal cancer, conditions having low-grade systemic inflammation (30, 31). Concordantly, high DF intake correlates with reduced incidence of disease and mortality (32–35). DF preserves the gastrointestinal immune barrier (36, 37), with dysfunction triggering autoimmune disease and IBD development (13, 35, 38). These beneficial effects are attributed to fermentation products, mainly SCFAs, interacting with small intestinal immune cells before its degradation by microbial enzymes (39).

The GM and the mucosal immune system is a complex ecosystem, involving mutualistic GM-host relationship, where microorganisms convert diet carbohydrates, proteins, and fats into metabolites, having positive or negative health effects (40). The human digestive system lacks enzymes to digest complex polysaccharides, such as pectins, xylan or celluloses, consequently reaching the colon with their intact structure, and subsequently fermented by GM bacteria (41, 42).

GM has numerous enzymes, 16 families being carbohydrate esterases, 22 polysaccharide lyase, with 130 glycoside hydrolases standing out, allowing DF fermentation, giving GM flexibility to adapt to many substrates (24). Firmicutes and Actinobacteria phyla are the main bacteria responding to DF, although few enzymes initiate substrate degradation (43). The main substrates for bacterial fermentation and SCFAs production are inulin, wheat and oat bran, cellulose, guar gum, pectin, and resistant starch; the latter an important source for butyrate production (2). Phylum Bacteroidetes members are major acetate and propionate producers, while phylum Firmicutes produce mostly butyrate (44, 45).

The main human intestinal butyrate-producing bacteria are Faecalibacterium prausnitzii and Clostridium leptum, Ruminococcaceae family members, and Eubacterium rectale and Roseburia spp from the Lachnospiraceae family (24, 45). Additionally, sugar and/or lactate utilizing bacteria such as Eubacterium hallii and Anaerostipes spp. produce butyrate from lactate and acetate in a cross-feeding process (44). However, members of the phyla Fusobacteria, Proteobacteria, Actinobacteria, Spirochaetes and Thermotogae are potential butyrate producers, expressing genes encoding butyrate synthesis enzymes, such as butyryl-CoA dehydrogenase, butyryl-CoA transferase and/or butyrate kinase (46).

Production of other SCFAs is determined by Actinobacteria, such as the Bifidobacterium species, producing lactate during DF fermentation (47). Bifidobacteria metabolizes low molecular weight carbohydrates; Bifidobacterium longum subsp. infantis prefers short-chain fructo-oligosaccharides (48), additionally, a relevant phylum Verrucomicrobia member, the mucin degrader, Akkermansia muciniphila, produces acetate and propionate (45, 49).

Although metabolite production depends on the bacterial species capable of fermenting DF, their consumption is a good way to stimulate metabolite production through modulation of the GM composition.

SCFAs and Receptors

SCFAs are carboxylic acids produced by DF fermentation, having 1-6 carbon aliphatic tails, with acetate (C2), propionate (C3) and butyrate (C4) being the most abundant (2). Soluble DF rich diets are associated with less inflammation due to higher SCFAs production and stimulation with G-protein-coupled receptors (GPCR), i.e., the primary receptor for SCFA. GPCR inhibits NF-κB activation in immune cells and intestinal epithelial cells (IEC) (50). SCFAs profoundly impacts human health by being an energy for colonocytes, regulating glucose metabolism, fatty acids and cholesterol hepatic biosynthesis, inhibiting pathogen growth and reducing intestinal inflammation (51) and enhancing barrier function both in vitro and ex vivo (52–54) by altering TJs formation (Figure 1) (53, 55). An colonocyte energy source, butyrate is the most relevant SCFAs bacterial metabolite, regulating gene expression and inflammatory (40). Studies evaluating butyrate effect on
FIGURE 1 | Endogenous or dietary compounds and dietary-derived bacterial metabolites effects on the gut immune barrier. (1) Direct effect of dietary fiber. Some dietary fibers have been shown to have direct effects on immune cells. E.g., low degree of methyl esterification (Low-DM) pectin binds to TLR2, inhibiting TLR2-1 heterodimer activation, thus reducing NF-κB activation. (2) Bacterial fermentation of dietary fiber by SCFAs-producing bacteria. SCFAs inhibit histone deacetylases (HDACs) and thus NF-κB-induced pro-inflammatory mediators: (2A) induce neutrophil chemotaxis by binding to GPR43, (2B) promote IgA secretion (2C), stimulate Tregs proliferation and differentiation by activating GPR43 and inhibiting HDACs (2D), influence NLRP3 by activating GPR43 or GPR109A facilitating IL-18 expression, thus promoting repair and maintaining barrier function (2E, 2F). (3) Bacterial tryptophan metabolism: Indole promotes epithelial barrier function through the pregnane X receptor (PXR). Bacterial tryptophan metabolites are AhR ligands in ILCs, RORγt interacts with AhR stimulating IL-22 expression (3A, 3B), IL-22 promotes antimicrobial peptide expression and enhances goblet cell proliferation for mucin secretion (2E). (4) Bacterial bile acid metabolites: Gut metabolites-derived from microbiota, endogenous or dietary compounds participate in microbiota-host interactions, exerting diverse effects on epithelial or immune cells through different signaling pathways. Secondary bile acids regulate epithelial integrity by binding to the farnesoid X receptor (FXR) in epithelial cells (4A), regulate macrophages differentiation into M2 profile via TGR5 and FXR activation, reversing inflammatory pathways producing IL-10 (4B), with further IL-10 production by Treg (2D). Additionally, TGR5 signaling involves NF-κB inhibition, and FXR signaling repressing NF-κB-responsive elements (NRE) in macrophages and dendritic cells (4B, 4C).
intestinal permeability, both in vitro and ex vivo, indicate low concentrations of butyrate are beneficial, while excessive luminal concentration could cause mucosal barrier disruption (52, 53). It has been demonstrated that high concentrations of SCFAs induces intestinal mucosa injury in newborn rats, but although maturation dependent, this injury disappears in mature mucosal defense (56). Additional studies (52) show that high butyrate concentrations disrupt assembly of TJ to the intestinal barrier, proposing that barrier function regulation by low butyrate concentrations in Caco-2 cell monolayers facilitates TJ assembly in a dynamic process mediated by AMP-activated protein kinase (AMPK) activation (53).

Both DF and butyrate are important components and metabolites involved in managing inflammatory diseases (57). SCFAs suppress IL-8 secretion and expression (58–61), although, high butyrate doses has the opposite effect (61). Understanding butyrate action in reducing inflammation is important, especially the histone acetylation mechanism (62), requiring more study as butyrate metabolizes to Acetyl-CoA, activating histone acetyltransferase (HAT), affecting cell turnover, structure and function and tumoricity, although with paradoxical effects (63, 64). Butyrate permeate the cell membrane by passive diffusion or is absorbed by apically proton-coupled monocarboxylate transporter 1 (MCT1) and sodium-coupled monocarboxylate transporter 1 (SMCT1) on IECs and/or immune cells (65). MCT1 primarily transports butyrate and is induced by SCFAs, inhibiting HDACs through MCT1 (66).

Cellularly, SCFAs activate signaling pathways through GPCRs: GPR41, GPR43 and GPR109A (expressed in colonic epithelium enteroendocrine cells, polymorphonuclear immune cells and smooth muscle cells) with different affinities (Figure 1). GPR41 and GPR43 have a role in the immune surveillance of the colonic mucosa towards microbial activity (67), whilst GPR109A inhibits NF-kB activation as a tumor suppressor (68). Active absorption of butyrate is reduced in IBD with decreased MCT1 expression in inflamed mucosa of UC patients (69), possibly due to high TNF-α levels (70) or reduced butyrate-producing bacteria, causing faulty oxidization (71, 72), potentially indicating that butyrate reduces IL-8 expression mediated by GPR109A.

GPR41 and GPR43 activate the NLRP3 inflammasome (73), triggering IL-1β and IL-18 secretion (74, 75), and GPR43 regulates immune cells in experimental inflammation (36, 37), with sodium butyrate increasing disease severity in DSS model of germ-free mice (76). Butyrate modulates immune cells, such as macrophages (77), dendritic cells (78) and lymphocytes (77), and inhibits cytokines, such as IL-12p70 and IL-23, polarizing naïve CD4+ T cells towards the Th1 and Th17 subtypes (79). Butyrate affects the mucosal immune system through Treg expansion, and inhibits HDAC activity in dendritic cells, resulting in retinaldehyde dehydrogenase 1 (RALDH1) and GPR109A expression (77). RALDH1 modulates naïve T cell differentiation towards Treg producing IL-10 (77, 80, 81), with butyrate also enhancing Foxp3 expression and Treg differentiation, reducing inflammation (80).

GM in IBD patients is characterized by loss of intraindividual diversity, with higher abundance of Proteobacteria and lower of Firmicutes. Interestingly, butyrate-producing bacteria Faecalibacterium prausnitzii, Ruminococcus torques, Roseburia inulinivorans, Blautia faecis, and Clostridium lavalense are reduced in patients (82–85), with lower luminal butyrate concentrations (86) and higher C-reactive protein, reflecting increased inflammation (84). Furthermore, a reduced butyrate-synthesis pathway has been described in IBD patients, with butyryl-CoA:acetate CoA-transferase (BCoAT) gene content inversely associated with disease activity and dysbiosis, being more evident in CD, and may relate to reduced DF intake (87). Alternatively, celiac disease associates with GM alterations, although no SCFA quantity differences or composition exist between celiac patients and healthy patients (88). Interestingly, prolonged administration of oligofructose-enriched inulin in children with celiac disease (under a gluten-free diet), has a moderate effect on GM composition, while SCFA production is stimulated in celiac children (89).

Accordingly, activated NF-kB in UC patients colonic mucosa is reduced by butyrate and SCFAs enemas (100 nM), directly correlating with disease activity (90, 91), with no effect in patients in remission (92). Depending on butyrate physiological concentration, it can be beneficial, with fewer molecules reaching colonocytes, as mucus layer prevents excessive concentrations towards epithelial cells, and increasing MUC2 expression (93). Regarding the above, the fact that butyrate effect is variable, is related to the physiological irrigation of this SCFA. At these or other doses, it is likely that in an in vivo IBD model, fewer butyrate molecules reach the colonocytes than in an in vitro model, since the colonic epithelium is covered by a thick mucus layer preventing passage of excessive concentrations of butyrate into the cell. Consequently, as butyrate concentration gradients run from the crypt-lumen axis and the luminal axis proximal-distal, colonocytes at the crypt base are exposed to an estimated µM concentration range, thus explaining its variable effects on inflammation.

**Dietary Fiber and TLRs Interaction: Direct Effects**

Certain DF have a direct anti-inflammatory effect by directly interacting with pattern recognition receptors (PRRs), mainly Toll-like receptor (TLR) 2 and 4, or Galectin-3 in intestinal immune barrier cells. Accordingly, low-grade methyl esterification pectins (Low-DM) block innate immune receptors, with pectin directly inhibiting pro-inflammatory TLR2-TLR1 pathway (without affecting TLR2-TLR6 tolerogenic pathway in vitro) (Figure 1) and preventing clinical symptoms in a TLR-2 dependent doxorubicin-induced ileitis murine model (65). Additionally, low-DM citric pectin suppresses TLR-induced inflammatory cytokine expression in a mouse model of endotoxin shock (94). Moreover, apple pectin oligo-galactan exhibits a protective efficacy in a murine model of dextran sulfate sodium (DSS)-induced colitis, decreasing LPS-induced TNF-α, and is probably associated to a mechanism comprising TLR4 internalization and redistribution (95). Similarly, resistant starch (RS) also binds predominantly to TLR2 and/or TLR5 in dendritic cells, affecting PRR signaling (96).

Pectin directly interacts with TLR2, inhibiting the proinflammatory signaling pathway, thereby contributing to barrier function and preventing colorectal cancer development.
(97). Similarly, β2 fructans also regulate mucosal homeostasis through activation of TLR2 (to a lesser degree TLR4, TLR5, TLR7, TLR8 and Nucleotide Binding Oligomerization Domain Containing 2; NOD2) producing IL-10/IL-12 in mononuclear cells (in chain length-dependent manner) (98), and regulating barrier function in T84 cells (99). Wheat bran and peanut fiber also improve intestinal barrier function, changing GM composition and TLR2 expression in pigs (100). Likewise, chicory pectin and intact guar gum DF exhibit an anti-inflammatory effect in a murine model of DSS-induced colitis decreasing proinflammatory expression (101, 102). Additionally, bengkoang DF binds to TLR4, favoring phagocytic activity in J774.1 macrophages (103).

Soluble DF has immunomodulatory effects by influencing human peripheral blood mononuclear cells (PBMCs) functions (independent of SCFA production) (39), and has symbiotic effects with certain Lactobacillus, synergistically stimulating IL-6 and IL-8 production in immune cells (104). Inulin and short-chain fructo-oligosaccharides (scFOS) directly promote, in a GM-independent manner, specific intestinal barrier function in a damage-induced model of Enterohemorrhagic E. coli (105).

All these fibers can be instrumental in prevention or lowering symptoms of chronic inflammatory conditions where the aforementioned gut epithelial processes are involved. Examples are celiac disease which results from oral tolerance to gluten breakdown in subjects carrying HLA-DQ2 or HLA-DQ8 variants (106). High maternal fiber intake during pregnancy is associated with a lower risk for celiac disease in children, while gluten intake associates with a high risk, suggesting that high dietary fiber and low gluten intake during pregnancy is a protective factor for celiac disease (107). The mechanisms are not yet clear but might be associated to the aforementioned protective effects of DF on gut epithelial immune barrier function.

Galectin-3, extracellularly or intracellularly expressed in immune and epithelial cells, plays a fundamental role in health and disease (108), interacting with carbohydrates and intracellular proteins. Galectin-3, acts as a PRR inducing innate responses against pathogens (109), enhanced by pectins (109), through galactose residues or arabinose side chains with rhamnogalacturonan I (RG-I) and rhamnogalacturonan II (RG- II) (110).

**Secondary Bile Salts and Receptors**

Secondary BAs are potent nuclear receptor ligands, binding to farnesoid X receptor (FXR), vitamin D receptor (VDR) and pregnane X receptor (PXR), additionally acting as endogenous agonists for the microbial G protein-coupled bile acid receptor (TGR5). These receptors play an important role in BAs synthesis, regulation and metabolism (122) and are relevant in different pathological processes (Figure 1). BAs receptors are expressed in IECs, hepatocytes, liver parenchyma, muscles, neurons, among others (123), as well as in immune cells (124–127), responding to endogenous and bacterial antigens. In BAs metabolism by FXR, biliary acidosis inhibition by CYP7A1 inhibition is an important step, occurring via the hepatic bile salt export pump, inducing small heterodimer partner (SHP) expression. SHP inactivates the hepatic homologous receptor-1 (LRH-1) inhibiting CYP7A1 expression (128). Alternatively, FXR activated by BAs induces FGD15/19 to FGFR4 binding, inhibiting CYP7A1 (129).

During inflammation, FXR regulate intestinal immune responses driven by GM, with low-grade chronic inflammatory disorders associated to dysbiosis and altered BAs profiles in humans (130). IBD patients exhibit a low content of bile salt biotransformation genes (mostly from Firmicutes phylum) as well as low secondary and high primary BAs levels compared to healthy subjects (131, 132). Also FXR null mice are unable to reduce intestinal inflammation, promoted by GM-LPS stimulation of NF-kB and inflammatory cell recruitment (133). Additionally, antibiotic-induced GM alterations allow C. difficile spore germination and inhibit BAs-producing bacteria, depleting BAs production (134) and, thus inhibit FXR activation. Additionally, FXR deficiency in a ApoCmin/+ and azoxymethane (AOM)-DSS murine model of colon carcinogenesis (associated with chronic colitis), resulted in premature death and increased tumor progression through Wnt signaling pathway activation in macrophages, neutrophils (135). Moreover, BAs deficiency (due to bile duct obstruction) associates with bacterial overgrowth and translocation, intestinal damage, reverted by BAs or GW4064 (FXR agonist) administration (136). Obeticholic acid (OCA) also a FXR agonist, decreases severity, maintaining epithelial barrier

via bile salt hydrolases (BSH) hydrolyzing the amide bond and transforming deconjugated primary BAs to secondary BAs, mainly by 7α-dehydroxylation reactions exerted by a limited number of bacteria (116).

While deconjugation is performed by numerous bacteria, BSH are encoded in different genus species: Lactobacillus, Bifidobacterium, Bacteroides and Clostridium, being more diverse in Firmicutes (117). Conversion of primary to secondary BAs by 7α-hydroxylation is a relevant microbial BAs transformations in humans (118), as cholic acid is transformed to deoxycholic acid (DCA) and chenodeoxycholic acid to lithocholic acid (LCA). 7α-dehydroxylation, is a characteristic of Clostridium (Clostridium hylemonae and C. scindens, the latter important in the production of LCA), as well as Eubacterium (119, 120). Bacterial BAs metabolism plays a fundamental role in systemic and intestinal health, since imbalances in BA-GM crosstalk associates with inflammatory and gastrointestinal disorders (121).
integrity and decreasing inflammatory cytokine production in a DSS or 2,4,6-Trinitrobenzene sulfonic acid (TNBS)-induced colitis murine model (125, 137), whilst isoDCA (secondary BA) induces peripheral Treg cells (138). Therefore, FXR rhythmically becomes a therapeutic IBD target, although, clinical trials using FXR agonists will be required.

GM activates TGR5 expression, affecting enteroendocrine cells, exhibiting immunomodulatory and anti-inflammatory effects (139), mainly in macrophages and monocytes (139). Importantly, TGR5 regulates energy metabolism and glucose homeostasis: inducing GLP-1 secretion, glucose metabolism, intracellular cAMP levels, transcription of type 2 iodothyronine deiodinase (Dio2) gene (encoding type 2 deiodinase (D2) converting thyroid hormone T4 into triiodothyronine, T3). Through TGR5 activation, BAs inhibit production of pro-inflammatory mediators IL-1, IL-6 and TNF-α, induced by LPS (140). Likewise, BSH-containing bacteria alters TGR5-mediated pro-inflammatory or anti-inflammatory activity, dissociating taurine or glycine from BAs.

TGR5 agonist effect associates with intestinal IL-10 increase (141). BAR501, a selective agonist of TGR5, protected mice from colitis by polarizing intestinal macrophages from M1 to M2 phenotype and reducing intestinal and circulating monocytes/macrophages (141, 142).

In celiac disease, immunologically mediated extraintestinal manifestations in the liver can occur. Both gut and liver, share lymphocyte recruitment and return routes, with gut T lymphocytes contributing to liver and biliary inflammation (143). The gut-liver axis describes a close metabolic and immunological connection between the intestine and the liver, and an imbalance or damage in this axis can trigger innate immune responses that induce liver damage or contribute to its progression (144). It should be noted that in celiac disease, the intestinal permeability, together with chemokine CXCR3, increase entry of food and bacterial antigens, as well as bacterial metabolites via the portal vein, triggering immune responses by activation of PPRs (CD14/TLR4 complex, inflammasome, etc.), generating liver inflammation and metabolism alterations. Alternatively, dysbiosis in this pathology produces an increase in intestinal permeability and mediates inflammatory processes, enhancing celiac disease immunopathology and altering BAs composition, impacting on hepatic FXR and TGR5, inflammation and BA metabolism (145, 146).

The above demonstrates a clear role of GM-BAs-FXR/TGR5 axis in Tregs, monocytes and macrophages regulation, highlighting the potential use of secondary BAs or other natural or synthetic ligands as new therapies in inflammatory pathologies.

TRYPOTOPHAN METABOLISM AND HEALTH EFFECT

Tryptophan Catabolism
Dietary proteins and peptides are normally digested in the small intestine, resulting in free amino acids actively absorbed from the intestinal lumen into the systemic circulation. Next to serving as nutritional source, proteins can serve as GM fermentable substrates when escaping from digestion in the small intestine and reaching the large intestine. Tryptophan (Trp) is an essential amino acid composed of a β-carbon, connected at position 3 of an indole group, naturally provided by poultry, milk, tuna, fish, cheese, bread, oats, prunes, chocolate, and peanuts. Of the 20 amino acids, Trp has the highest molecular weight and is a biosynthetic precursor of a large number of metabolites (147). Alternatively, it can be metabolized by the host in the kyneurine pathways or be utilized for serotonin synthesis in the brain and intestine; or by the GM, which can directly use Trp, partially limiting its availability, metabolizing approximately 4-6% indole, skatole, tryptamine and indole acid derivatives (148). Intestinal bacterial species convert Trp to tryptamine and indole-3-pyruvic acid (IPyA), additionally converting it to indole, indole-3-acetaldehyde (IAAId), and indole-lactic-acid (ILA). Furthermore, IAAId converts to indole-3-acetic acid (IAA) and tryptophol, and IAA indirectly converts to skatole through decarboxylation (148, 149). Lastly, IIA can convert to indole-acrylic acid (IAA) and subsequently to indole propionic acid (IPA) (150). Different bacterial species possess different catalytic enzymes, some cooperating with each other to generate a Trp metabolite (Table 1); for example, indole is produced by Firmicutes phylum members such as Enterobacter aerogenes, Clostridium limosum, C. tetani, C. lentoputrescens, C. bifermantans, C. melanomenatum, as well as some members of the Bacteroidetes, Fusobacteria and Proteobacteria phylums; alternatively, IAID is produced in a reduced number of species belonging to Firmicutes phyla, such as Lactobacillus johnsonii, L. reuteri, L. murinus and L. acidophilus (Table 1). The Trp bacterial metabolism is a complex process, with many bacterial strains having catalytic capacity against Trp, but many of them remain to be identified. Accordingly, understanding which bacterial consortia produce Trp metabolites is necessary, and considering the GM intervariability (151) will allow the design of targeted strategies to steer Trp metabolism production modulating GM composition through the diet.

As will be outlined in next sections of this review, Trp metabolites have many beneficial effects for gut epithelial barrier function.

A main Trp metabolite is indole (conserved molecule between kingdoms and species). It is produced by bacteria for biofilm formation, regulating bacterial motility and resistance against non-indole producing species such as Pseudomonas aeruginosa jhonsonii and Salmonella enterica (164). Using the enzyme tryptophanase, bacteria converts Trp to indole and numerous indole-derived metabolites such as IAID, IIA, ILA, and IA (Table 1) (165).

The endogenous and microbial Trp pathway (the kyneurine pathway), and the indole microbial pathway converge on the xenobiotic receptor, AhR, (located in the cytosol of resting cells) and when bound to its ligand, translocates into the nucleus heterodimerizing with AhR nuclear translocator (ARN), binding to dioxin-responding elements within enhancer and target gene promoter.

Bacterial Trp metabolites are low-affinity ligands for AhR, the most effective being indole, skatole, tryptamine, IPyA, IA and Indole-3-acetamide (IAM); whilst IAA, IPA, IIA and IAID the least active (166). Additionally, methyl-indoles and methoxy-
Indoles have synergistic effects in vitro (167), with different bacterial metabolites, such as SCFAs and secondary BAs.

Trp is an important regulator of inflammatory responses in mammals (Figure 1) (168), such as mice and pigs, with a low Trp diet making mice more susceptible to chemically induced inflammation (169). Also, it regulates bone remodeling, carcinogenesis, organ development, neurophysiology, metabolic diseases and, xenoprotection (170–174). As a mucosal protection against inflammation, Lactobacillus reuteri uses Trp to expand and generate an AhR ligand: IAID, contributing to IL-22 production (176, 177). Furthermore, IBD patients carrying CARD9 polymorphism have reduced faecal bacterial populations affect IBD severity is unknown. Additionally, GWAS studies in IBD patients have identified mutations impacting IL-22 pathways, especially in the Card9 gene sensing type-C lectins, as also witnessed in Card9 deficient mice, prone to DSS-induced colitis (176, 177). Concordantly, reduced serum Trp levels in patients negatively correlate with disease activity or C-reactive protein levels (178), although, determining if GM modification or indole-producing bacterial populations affect IBD severity is unknown.

AhR defective signaling contributes to pathogenic responses, witnessed in celiac disease patients, with AhR transcript decreased in IECs and peripheral mononuclear cells, although, an AhR agonist (6-Formylindolo(3,2-b)carbazole; Ficz), reduced pro-inflammatory cytokine, granulocyte B and perforin expression

### Indoles and Receptors

Bacterial indoles, such as IPyA, increase intestinal barrier function through PXR, decreasing TNF-α expression in enterocytes, whilst promoting goblet cell differentiation in female C57BL/6 mice (156). PXR/- mice show increased intestinal permeability and enhanced TLR4 expression, demonstrating direct chemical communication between gastrointestinal symbionts and PXR pathway in mucosal homeostasis (174). Interestingly, IPyA reduces intestinal permeability in high-fat diet mice, indicating that obese subjects with low IPyA levels have an imbalanced intestinal barrier function (175). Additional to intestinal barrier function and inflammatory response regulation, IPyA promotes goblet cell differentiation in mice (156).

Absence of Trp metabolizing bacteria impact on IL-22 immune regulation, with reduced IL-22 production seen in IBD. Additionally, GWAS studies in IBD patients have identified mutations impacting IL-22 pathways, especially in the Card9 gene sensing type-C lectins, as also witnessed in Card9 deficient mice, prone to DSS-induced colitis (176, 177). Furthermore, IBD patient’s carrying CARD9 polymorphism have reduced faecal AhR activity, Trp levels and GM production of AhR ligands, making GM an attractive target for modulation (176, 177). Concurrently, reduced serum Trp levels in patients negatively correlates with disease activity or C-reactive protein levels (178), although, determining if GM modification or indole-producing bacterial populations affect IBD severity is unknown.

| Trp Metabolite | Phylum | Bacterial species | Enzymes | Model | Refs. |
|---------------|--------|------------------|---------|-------|-------|
| Indole        | Firmicutes | Enterobacter aerogenes, Clostridium limosum, C. tetani, C. lentoputrenscens, C. bifermantans, C. melenomunatum. | Tryptophanase | Human gut content (150) | (150, 152, 154) |
| Bacteroidetes | Bacteroides ovatus, B. thetaiotaomicron. | | | Bacterial culture (152) | (152) |
| Fusobacteria  | Fusobacterium nucleatum | | | | |
| Proteobacteria | Escherichia coli, E. albertii | | | | |
| Indole-3-acetic acid (IAA) | Firmicutes | Lactobacillus reuteri, C. difficile, C. paraputricum, C. lituseburensis, C. paraputricum, E. cloacae, Peptostreptococcus ascharallyticus. | Indolepyruvate decarboxylase | Human gut content (150) | (150, 155) |
| Bacteroidetes | Parabacteroides distasonis, B. fragilis. B thetaiotaomicron, B. egerthii, B ovatus. | | | Bacterial culture (155) | (155) |
| Proteobacteria | E. coli | | | | |
| Actinobacteria | Bifidobacterium pseudolongum, B. adolescentis, B. longum subsp. Longum. | | | | |
| Indole propionic acid (IPA) | Firmicutes | C. botulinum, C. calortolerans, C. paraputricum, C. sporogenes. C. cadaveris, Rauschbrand bacillus. | Pyruvate:ferredoxin oxidoreductase | Human stool samples, DSS-induced colitis mice, cell culture (156) | (154–156) |
| Bacteroidetes | P. anaerobius, P. russelii, P. stomatis | Phenyllactic dehydrogenase | Human gut content (150) | Bacterial culture (152, 157) | (152, 157) |
| Indole-acrylic acid (IA) | Bacteroidetes | P. anaerobius, P. russelii | Phenylacetate dehydratase | Human gut content (150) | Bacterial culture (152, 157) | (152, 157) |
| Indole-3-acetylamide (IAM) | Firmicutes | L. johnsonii, L. reuteri, L. murinus, L. acidophilus. | Aminotransferase | Murine model (158, 159) | (158–160) |
| Indole-lactic acid (ILA) | Firmicutes | C. saccharolyticum, Eubacterium cylindroides, P. ascharallyticus. | | | |
| Bacteroidetes | B. ovatus, B. thetaiotaomicron | | | | |
| Proteobacteria | E. coli | | | | |
| Actinobacteria | B. pseudolongum, B. adolescentis | | | | |
| Indole-3-acetamide (IAM) | Proteobacteria | Burkholderia pyrocinia | Tryptophan-2-monooxygenase | Bacterial culture (162) | (162) |
| 3-Methyl-indole (skatole) | Firmicutes | E. rectale, Butyribrio fibrisolven | | | |
| Tryptamine | Firmicutes | Ruminococcus gravis, C. sporogenes | Tryptophan decarboxylase | Human gut content (150) | Bacterial culture (152, 157) | (152, 153) |
| Indole-3-pyruvic acid (IPA) | Firmicutes | E. coli, C. bifermentans, C. melanomenatum | Tryptophan aminotransferase | | (152) |
AhR activation by Ficz exposure, CD8
activating proliferation of colonic stem cells, epithelial barrier
by AhR-associated Src kinase phosphorylation of indolamine
signaling is responsible for at least two anti-in
flammation, and its relationship with GM.

Involvement of AhR in Intestinal Barrier Function
and Intestinal Immune Cells

Canonical (181), and non-canonical AhR signaling pathway have
been described, either at the genomic or non-genomic level
through association with other transcription factors, such as
NF-kB, or Src kinase. Inactive AhR joins to Src kinase in the
cytosol, when an agonist interacts with AhR, a conformational
change occurs allowing (170, 189–191). Non-genomic AhR
signaling is responsible for at least two anti-inflammatory
outcomes, LPS exposure induce suppressive effects mediated
by AhR-associated Src kinase phosphorylation of indolamine
2,3-dioxygenase IDO1, inducing TGF-β transcription in
dendritic cells (151), or IL-10 production (192). Interestingly,
after AhR activation by Ficz exposure, CD8αα+ TCRβ+ intraepithelial lymphocytes (IELs) resist apoptosis with AhR,
IL-15 and IL-10 up-regulation, and IFN-γ reduction in a colitis
model (193). In IBD, immune cells express low levels and altered
activity of AhR, maintained by decreased GM-derived AhR
ligand production, mainly bacterial Trp metabolites and
butyrate (151). Accordingly, depleted dietary AhR ligands alter
GM composition and function (194), with Trp metabolites
present in murine cecal content and human feces, activating
AhR, and are considered intestinal activity biomarkers (182).

A novel AhR activator is 1,4-dihydroxy-2-naphthoic acid (DHNA),
a precursor of vitamin B12 produced by Propionibacterium
freudenreichii ET-3, inducing intestinal anti-microbial protein
synthesis, altering GM composition and inhibiting murine DSS-
induced colitis (196). Similarly, indole-3-ethanol, indole-3-pyruvate
and indole-3-ethanol protect against increased gut permeability in
a murine DSS-induced colitis model (195). AhR maintain intestinal
permeability, with Ficz promoting goblet cell differentiation through
AhR-pErk1/2 signaling pathway, and ameliorating DSS-induced colitis
(197). Furthermore, after intestinal reperfusion ischemia and hypoxia,
AhR activation increases Notch1 signaling, thus reducing epithelial
barrier dysfunction in vivo and in vitro (198). The epithelial barrier
function is regulated by direct (AhR activation by Ficz inhibit Par-6
expression through the Ap-2γ pathway) (199) and indirect mechanisms
(AhR activation by Ficz prevented TNF-α/IFN-γ-induced decrease in
 TJ disruption) (200), with AhRs increasing TJ protein expression in
response to IL-22 produced by CD4+ T cells (201). Finally, AhR
expression in IELs is abrogated by miR-124 in active CD patients (202),
therefore, AhR inhibits pro-inflammatory pathways in IECs preserving
intestinal permeability.

Macrophages as Potential Target in
Intestinal Inflammatory Disorders

Intestinal macrophages are central in establishing and maintaining
mucosal homeostasis, with its dysregulation generating loss of
tolerance towards dietary antigens and GM, underlying IBD
chronic inflammation. Together with SCFAs, bacterial Trp
metabolites control susceptibility to intestinal inflammation
through AhR activation pathways in macrophages. AhR deletion
in intestinal mucosa CD11c+ dendritic cells and certain macrophage
subsets increases the stem cells in the ileal epithelium and
differentiates epithelial precursors, causing greater susceptibility to
murine DSS-induced colitis (203). Furthermore, a recent study
observed that I3C treatment in C57BL/6 mice reduced
macrophages expressing F4/80, demonstrating a diminished
infiltration of innate immune cells into the colon. This effect was
not observed in Ahr-/- mice, suggesting that the therapeutic effects
of I3C was AhR-dependent (204). Alternatively, a synthetic
pelargonidin (water soluble anthocyanidin) can be transacted
by the AhR, attenuating pro-inflammatory activities of Raw264.7
macrophages in an AhR-dependent manner. The administration of
this compound resulted in a dose-dependent attenuation of TNBS-
induced colitis in Balb/c mice and promoted M2 macrophage
expansion (205).

AhR negatively regulates LPS-mediated inflammatory responses
in macrophages, inducing IL-6 and TNF-α production in AhR-
deficient macrophages compared to WT cells. Furthermore, AhR+/mice are more sensitive to LPS-induced lethal shock, similarly seen
in STAT1 deficient animals, indicating that AhR complexes with
STAT1 and NFκB in LPS-stimulated macrophages (206).

Accumulation of anti-inflammatory profile (M2)
macrophages in the intestinal microenvironment appears to be
crucial in restoring tissue homeostasis (207). Diet-derived
bacterial ligands capable of modulating macrophages towards
an M2 phenotype, AhR agonist-producing probiotics, or

BACTERIAL CATABOLITES AS ARYL
HYDROCARBON RECEPTOR (AHR)
LIGANDS: KEY ROLE IN GUT
MICROBIOTA AND IMMUNITY

AhR is a ligand-dependent transcriptional factor widely expressed
in immune, epithelial, endothelial, and stromal cells in barrier
tissues, and extensively studied in response to chemical
contaminants. AhR senses a wide range of intestine signals,
maintaining homeostasis between GM and host (181–183),
activating proliferation of colonic stem cells, epithelial barrier
functions, and regulating immune cells, such as RORγt
intraepithelial innate lymphoid cells (ILC3), T helper
lymphocytes (Th 17/22), pϕT lymphocytes, antigen presenting
cells and Foxp3+ Treg lymphocytes (151, 184–187). AhR response
to physiological ligands has become an interesting focus of research,
and the next section reviews current evidence on its molecular
interaction and function in the immune system in steady state and
intestinal inflammation, and its relationship with GM.

In addition, independent of GPCRs or MCT1 pathways,
butyrate activates the AhR, modulating the interaction between
diet, GM and host (151, 184, 185) therefore is reduced in IBD Thus,
butyrate, by inhibiting HDACs, increases CYP1A1 expression in a
AhR-dependent manner in Caco-2 and HT-29 cells (188).

AhR is a ligand-dependent transcriptional factor widely expressed
in immune, epithelial, endothelial, and stromal cells in barrier
tissues, and extensively studied in response to chemical
contaminants. AhR senses a wide range of intestine signals,
maintaining homeostasis between GM and host (181–183),
activating proliferation of colonic stem cells, epithelial barrier
functions, and regulating immune cells, such as RORγt
intraepithelial innate lymphoid cells (ILC3), T helper
lymphocytes (Th 17/22), pϕT lymphocytes, antigen presenting
cells and Foxp3+ Treg lymphocytes (151, 184–187). AhR response
to physiological ligands has become an interesting focus of research,
and the next section reviews current evidence on its molecular
interaction and function in the immune system in steady state and
intestinal inflammation, and its relationship with GM.

In addition, independent of GPCRs or MCT1 pathways,
butyrate activates the AhR, modulating the interaction between
diet, GM and host (151, 184, 185) therefore is reduced in IBD Thus,
butyrate, by inhibiting HDACs, increases CYP1A1 expression in a
AhR-dependent manner in Caco-2 and HT-29 cells (188).
synthetic AhR agonist analogs (designed to optimize their anti-inflammatory activities) administration, could provide future anti-inflammatory therapeutic approaches.

FUTURE DIRECTIONS

GM profoundly influences the inflammatory state via production of immunomodulating metabolites, making it an attractive target for therapeutic manipulation, using well-founded microbe- and metabolite-based therapies. Evidence discussed in the previous sections proposes various challenges and future directions to follow, for example:

- DF exhibit diverse effects on epithelial integrity, macrophages and dendritic cells (DCs) responses and is instrumental in enhancing the intestinal immune barrier through stimulating GM interaction with epithelium. However, to better understand DF impact, human studies controlling factors, such as diet, DF functional or nutraceutical-based foods to limit disease development are needed.
- Both IBD and celiac disease are characterized by alterations in the GM composition, SCFAs production, energy supply to colonocytes and local mucosal inflammation. Thus, GM empirical modulation can increase SCFAs-producing bacteria in vitro and in vivo, enriching its diversity, demonstrating clinical and histological improvement.
- Modulation of GM and secondary BAs profile represent novel therapeutic approaches to manage intestinal diseases such as IBD and colorectal cancer. Future research could elucidate secondary BAs effects on their receptors revealing opportunities for prevention and control of inflammatory diseases.
- The connections between Trp catabolites and human health are promising but needs further studies. By understanding their dynamics and functional implications for stimulating anti-inflammatory pathways mediated by PXR and AhR, maintaining intestinal barrier integrity, novel opportunities for therapeutic strategies might be developed.
- The mechanisms responsible for intestinal inflammation resolution needs further clarification. M2 macrophages accumulation in the intestinal microenvironment appears crucial. Identifying and studying environmental signals regulating phenotypes and functions of intestinal macrophages, such as AhR ligands, is essential in homeostasis and inflammation. Modulating monocytes to mature M2 macrophages transition through new identified molecules and pathways could promote remission of chronic states.

CONCLUSIONS

GM has positioned itself as an element that greatly impacts both intestinal and systemic immunity. A better understanding of GM importance, its metabolites, interacting receptors, the transcriptional regulation metabolites exert, and eventual interactions between various metabolites, provide countless possibilities in the prevention and treatment of inflammatory pathologies in western societies (obesity, diabetes, hypertension, neurodegenerative disorders, among others). Intriguingly, there is an overlap with respect to the molecules regulating both intestinal and immune homeostasis and how the deletion of either one of these metabolites or its receptors is capable of affecting the proper functioning of the host. Alternatively, the crosstalk between bacterial metabolites and possible convergences on pathways of interest in the modulation of local and/or systemic immune responses, becomes an attractive area that could be exploited to maintain intestinal and systemic homeostasis.

Many questions need solving and many challenges remain, however, is clear that the manipulation of intestinal health and immunity through receptors, enzymes and transcription factors is a reality. Furthermore, the identification of important commensals in GM-host interactions and the production of bioactive molecules could open up a greater number of possibilities that will determine the importance of GM and its metabolites in the susceptibility and progression of inflammatory pathologies of the gastrointestinal tract.

Challenges exist in selecting and delivering the correct bacteria strains and/or bacteria clusters to promote bacteria abundance and metabolite loss in the patients. Faecal microbiota transplantation has been proposed as a new treatment, mainly for Clostridium difficile infection and Crohn’s disease. However, despite being effective in alleviating symptoms, this procedure has drawbacks associated with safety of the transplanted inoculum and the difficulty of standardizing their bacterial content. Therefore, rational design of standardized consortia of intestinal bacteria for the efficient and safe treatment of these pathologies represent an alternative to faecal microbiota transplantation; associated to production of different bacterial metabolites inhibiting inflammatory signaling, thus reducing inflammation. Alternatively, the promotion of healthy food consumption, rich in essential substrates in the synthesis of bacterial metabolites, as well as foods or food stuffs capable of modulating GM, could limit a wide range of inflammatory diseases prevalent nowadays.

AUTHOR CONTRIBUTIONS

NG wrote most of the review. PV and MH participated reviewing and critically correcting the manuscript, on manuscript structure and supervised the work. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the National Agency for Research and Development (ANID)/Scholarship Program/DOCTORADO BECAS NACIONAL/2020 – 21200669, FONDECYT 1170648, Redes 180134 and FONDAP 15130011 Grants (MAH).

ACKNOWLEDGMENTS

We wish to thank David Cox for his editing. Graphical abstract created with BioRender.com.
41. Carlson JL, Erickson JM, Hess JM, Goud TJ, Slavin JL. Prebiotic Dietary Fiber and Gut Health: Comparing the In Vito Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide. *Nutrients* (2017) 9(12):1361. doi: 10.3390/nu9121361

42. Whisner CM, Castillo LF. Prebiotics, Bone and Mineral Metabolism. *Calcif Tissue Int* (2018) 102(4):443–79. doi: 10.1007/s00223-017-0339-3

43. Afia ML, Strang D, Tappia PS, Graham M, Van Domselaar G, Forbes JD, et al. A Randomized Trial to Determine the Impact of a Digestion Resistant Starch Composition on the Gut Microbiome in Older and Mid-Age Adults. *Clin Nutr* (2018) 37(3):797–807. doi: 10.1016/j.clinu.2017.03.025

44. Louis P, Flint HJ. Diversity, Metabolism and Microbial Ecology of Butyrate-Producing Bacteria From the Human Large Intestine. *FEMS Microb Lett* (2009) 294(1):1–8. doi: 10.1111/j.1574-6968.2009.01514.x

45. Louis P, Flint HJ. Formation of Propionate and Butyrate by the Human Colon Microbiota. *Environ Microb* (2017) 19(1):29–41. doi: 10.1111/1462-9920.13589

46. Vital M, Howe AC, Tiedje JM. Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing (Meta)Genomic Data. *MBio* (2014) 5(2):1–11. doi: 10.1128/mBio.00889-14

47. Riviere A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol* (2016) 7:979. doi: 10.3389/fmicb.2016.00979

48. Martinez-Gutierrez P, Ratering S, Juarez-Flores B, Godinez-Hernandez C, Geisser-Plaum R, Prell F, et al. Potential Use of Agave Salamiana as a Prebiotic That Stimulates the Growth of Probiotic Bacteria. *Lwt* (2017) 84:151–9. doi: 10.1016/j.lwt.2017.05.044

49. Derrien M, Vaughan EE, Plodge CM, de Vos WM. Akkermansia muciniphila Gen. Nov., Sp. Nov., a Human Intestinal Mucin-Degrading Bacterium. *Int J Syst Evol Microbiol* (2004) 54(5):1469–76. doi: 10.1099/ijsem.0.02873-0

50. Kellow NJ, Coughlan MT, Reid CM. Metabolic Benefits of Dietary Prebiotics in Human Subjects: A Systematic Review of Randomised Controlled Trials. *Br J Nutr Cambridge Univ Press* (2014) 111:1147–61. doi: 10.1017/S0007114513003607

51. Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of Short-Chain Fatty Acid Metabolism and Mucosal Mast Cells in Rat Intestine. *Cell Tissue Res* (2006) 324(3):353–60. doi: 10.1007/s00441-005-0140-x

52. Asarat M, Vasiljevic T, Apostolopoulos V, Donkor O. Short-Chain Fatty Acids Regulate Secretion of IL-8 From Human Intestinal Epithelial Cell Lines In Vitro. *Immunol Invest* (2015) 44(7):678–93. doi: 10.1080/08820139.2015.1085389

53. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate Enhances the Activation of the Akt Signaling Pathway. *Am J Physiol Gastrointest Liver Physiol* (2012) 303:1126–33. doi: 10.1152/ajpgi.00308.2012

54. Karaki SI, Mitsui R, Hayashi H, Kato I, Sugiyama H, Iwana MA, et al. Short-Chain Fatty Acid Receptor, GPR43, is Expressed by Enterococcaceae Cells and Mucosal Mast Cells in Rat Intestine. *Cell Tissue Res* (2007) 324(3):353–60. doi: 10.1007/s00441-005-0140-x

55. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaparakasam JP, Downing BB, et al. GPR109a is a G-protein-coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon. *Cancer Res* (2009) 69(7):2826–32. doi: 10.1158/0008-5472.CAN-08-4466

56. Thibault R, De Coppet P, Daly K, Bourrellie A, Cuff M, Bonnet C, et al. Down-Regulation of the Monocarboxylate Transporter 1 Is Involved in Butyrate Deficiency During Intestinal Inflammation. *Gastroenterology* (2007) 133(6):1916–27. doi: 10.1053/j.gastro.2007.08.041

57. Nancy S, Blanvillain E, Parmentier B, Florue B, Bayet C, Bienvenu J, et al. Infliximab Treatment Does Not Induce Organ-specific or Nonorgan-specific Autoantibodies Other Than Anti Nuclear and Anti-Double-Stranded DNA Autoantibodies in Crohn’s Disease. *Inflamm Bowel Dis* (2005) 11(11):986–91. doi: 10.1097/01.mib.0000186048.07799.78

58. De Preter V, Bulteel V, Suenaert P, Geboes KP, De Hertogh G, Luypaerts A, et al. Inflammatory Bowel Disease and Concomitant Uveitis: A Systematic Review. *Arthritis Rheumatol* (2018) 70(1):24–36. doi: 10.1002/art.39868

59. Roediger WVE. The Starved Colon Diminished Mucosal Diminished Absorption, and Colitis Nutrition. *Dis Colon Rectum* (1990) 33(10):858–62. doi: 10.1007/BF02051922

60. Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 Inflammasome and its Inhibitors: A Review. *Front Pharmacol* (2015) 6(NOV):1–9. doi: 10.3389/fphar.2015.00262

61. Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 Inflammasome in Inflammatory Diseases. *Nat Rev Drug Discovery* (2018) 17(8):588–606. doi: 10.1038/s41573-018-0041-z

62. Rabe H, Pohlm J, Vasseur P, Petit-Paris I, Jigo F, Favot L, et al. IL-1β-Induced Skin Inflammation in Mice is Dependent on IL-1R1 and MyD88 Signaling But Independent of the NLRP3 Inflammasome. *Eur J Immunol* (2015) 45(10):2847–57. doi: 10.1002/eji.201445215

63. Kesho M, Vachharajani N, Liu M, Harb H, Pautz S, Wolff S, et al. The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4+ T Cells. *Front Immunol* (2017) 8:1036. doi: 10.3389/fimmu.2017.01036

64. Kaisar MM, Pelgrom LR, van der Ham AJ, Yazdanbakhsh M, Everts B. Butyrate Conditions Human Dendritic Cells to Prime Type 1 Regulatory T Cells Via Both Histone Deacylation Inhibition and G Protein-Coupled Receptor 109A Signaling. *Front Immunol* (2017) 8:1036. doi: 10.3389/fimmu.2017.01429
78. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis. Immunity (2014) 40 (1):128–39. doi: 10.1016/j.immuni.2013.12.007

79. Nastaci C, Fredholm S, Willerslev-Olsen A, Hansen M, Bonefeld CM, Geisler C, et al. Butyrate and Propionate Inhibit Antibiotic-Specific CD8+ T Cell Activation by Suppressing IL-12 Production by Antigen-Presenting Cells. Sci Rep (2017) 7(1):1–10. doi: 10.1038/s41598-017-15099-w

80. Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: A Double-Edged Sword for Health? Adv Nutr (2018) 9(1):21–9. doi: 10.1093/advances/nmx009

81. Nowarski R, Jackson R, Gagliani N, De Zoete MR, Palm NW, Bailis W, et al. Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell (2015) 161(6):1444–56. doi: 10.1016/j.cell.2015.10.072

82. Sokol H, dicte Pigneur B, Watterlot L, Ladhari O, Bernu-deHurum LG, Gratadoux J-J, et al. Faecalibacterium prausnitzii is an Anti-Inflammatory Commensal Bacterium Identified by Gut Microbiota Analysis of Crohn Disease Patients. Proc Natl Acad Sci USA (2008) 105(43):16731–36. doi: 10.1073/pnas.0804812105

83. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, et al. Increased Butyrate-Producing Bacteria in Inflammatory Bowel Disease. Gut (2014) 79:29. doi: 10.1136/gut.40.4.485

84. Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Sartor RB. The Intestinal Microbiota in Inflammatory Bowel Disease. Am J Physiol - Gastrointest Liver Physiol (2004) 287(6 50):1168–74. doi: 10.1152/ajpgi.00219.2004

85. Ihashico S, Yabe T, Kitsukage K, Citrus Pectin Attenuates Endotoxin Shock Via Suppression of Toll-like Receptor Signaling in Peyer’s Patch Myeloid Cells. J Nutr Biochem (2017) 50:38–45. doi: 10.1016/j.jnutbio.2017.07.016

86. Liu L, Li YH, Niu YB, Sun Y, Guo ZL, Li Q, et al. An Apple Oligogalactan Prevents Inflammation and Carcinogenesis by Targeting LPS/TRL4/NF-κB Pathway in a Mouse Model of Colitis-Associated Colon Cancer. Carcinogenesis (2010) 31(10):1822–32. doi: 10.1093/carcin/bgp076

87. Bermudez-Brito M, Rollán P, de HA, Paat MM, de Vos P. Resistant Starches Differentially Stimulate Toll-like Receptors and Attenuate Proliferative Cytokines in Dendritic Cells by Modulation of Intestinal Epithelial Cells. Mol Nutr Food Res (2015) 59(9):1814–26. doi: 10.1002/mnfr.201500148

88. Beukema M, Jermendy E, Schols HA, de Vos P. The Influence of Calcium on Pectin’s Impact on TLR2 Signalling. Food Funct (2020) 11(9):7427–32. doi: 10.1039/D0FO01703E

89. Vogt L, Ramsamy U, Meyer D, Pullens G, Venema K, Faas MM, et al. Immune Modulation by Different Types of β–1 Fructans Is Toll-Like Receptor Dependent. PloS One (2013) 8(7):1–12. doi: 10.1371/journal.pone.0068367

90. Vogt LM, Meyer D, Pullens G, Faas MM, Venema K, Ramsamy U, et al. Toll-Like Receptor 2 Activation by β–1 Fructans Protects Barrier Function of 184 Human Intestinal Epithelial Cells in a Chain Length-Dependent Manner. J Nutr (2014) 144(7):2002–8. doi: 10.3945/jn.114.191643

91. Chen H, Mao X, He J, Yu B, Huang Z, Yu J, et al. Dietary Fibre Affects Intestinal Mesocullar Barrier Function and Regulates Intestinal Bacteria in Weaning Piglets. Br J Nutr (2013) 110(18):1387–48. doi: 10.1017/S0007114513001293

92. Sabater C, Molina-Tijeras JA, Vezza T, Corzo N, Montilla A, Utrilla P. Intestinal Anti-Inflammatory Effects of Artichoke Pectin and Modified Pectin Fractions in the Dextran Sulfate Sodium Model of Colitis Artificial Neural Network Modelling of Inflammatory Markers. Food Funct (2019) 10(12):7793–805. doi: 10.1039/C9FO02221I

93. Van Hung T, Suzuki T. Guar Gum Fiber Increases Suppressor of Cytokine Signaling-1 Expression Via Toll-Like Receptor 2 and Dectin-1 Pathways, Regulating Inflammatory Response in Small Intestinal Epithelial Cells. Mol Nutr Food Res (2017) 61:1–39 p. doi: 10.1002/mnfr.201700048

94. Kumalasari ID, Nishi K, Putra ABN, Sugahara T. Activation of Macrophages Stimulated by the Bengkoang Fiber Extract Through Toll-Like Receptor 4. Food Function (2014) 5(7):1403–8. doi: 10.1002/fsf2.1065

95. Lépine A, de Vos P. Symbiotic Effects of the Dietary Fiber Long-Chain Inulin and Probiotic Lactobacillus acidophilus W37 can be Caused by Direct, Synergistic Stimulation of Immune Toll-Like Receptors and Dendritic Cells. Mol Nutr Food Res (2018) 62(15):1–28. doi: 10.1002/mnr.280251

96. Wu RY, Abdullah M, Määttänen P, Pilar AVR, Scruten E, Johnson-Henry KC, et al. Protein Kinase Cε Signaling is Required for Dietary Prebiotic-Induced Strengthening of Intestinal Epithelial Barrier Function. Sci Rep (2017) 7(9):2017:1–10. doi: 10.1038/srep40820

97. Liu E, Lee H-S, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, et al. Risk of Pediatric Celiac Disease According to HLA Haplotype and Country. Engl J Med (2014) 370(1):37–47. doi: 10.1056/NEJMoa1313977

98. Lund-Pedersen NA, Tapia G, Mählard K, Brantsøer AL, Eggesbo M, Mandal S, et al. Maternal Fibre and Glutene Intake During Pregnancy and Risk of Childhood Celiac Disease: The MoBa Study. Sci Rep (2020) 10(1):1–9. doi: 10.1038/s41598-020-73244-4

99. Sciacchitano S, Lavra L, Morgante A, Uliervi A, Magi F, De Francesco GP, et al. Gaeclitin-3: One Molecule for an Alphabet of Diseases, From A to Z. Int J Mol Sci (2018) 19(2):379. doi: 10.3390/ijms19020379

100. Díaz-Álvarez L, Ortega E. The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses Against Pathogens. Mediators Inflammation (2017) 2017:19273547. doi: 10.1155/2017/927354

101. Gao X, Zhu Y, Sun L, Peng X, Zhang T, Xue H, et al. The Inhibitory Effects of a Rhangnagpolacturane (1–9)D Domain From Ginseng Pectin on Galectin-3 and its Structure-Activity Relationship. J Biol Chem (2013) 288(7):3935–65. doi: 10.1074/jbc.M113.482315

102. De Aguilar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic Roles of Bile Acid, Bile Acids in Metabolism. Cell Metab (2013) 17(5):657–69. doi: 10.1016/j.cmet.2013.03.013

103. Sayin SI, Wahlström A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Taurouricosodeoxycholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab (2013) 17(2):225–35. doi: 10.1016/j.cmet.2013.01.003

104. Ma H, Patti ME, Endocrinologist A. Bile Acids, Obesity, and the Metabolic Syndrome. Best Pract Res Clin Gastroenterol (2012) 26(4):573–83. doi: 10.1016/j.bpg.2014.07.004
Hakkola J, Rysä J, Hukkanen J. Regulation of Hepatic Energy Metabolism from Microbial Fermentation of Protein. *Mol Nutr Food Res* (2013) 57(3):523–35. doi: 10.1002/mnfr.201200594

Włodarska M, Luo C, Kolde R, d'Hennezel E, Annand JW, Heim CE, et al. Indoleacrylic Acid Produced by Commensal Peptostreptococcus Species Suppresses Inflammation. *Cell Host Microbe* (2012) 21(2):35–36. doi: 10.1016/j.chom.2011.06.007

Debhar-Daumler C, Seubert A, Schmitt G, Heider J. Simultaneous Involvement of a Tumour-Containing Aldehyde: Ferredoxin Oxidoreductase and a Phenylacetaldelyde Dehydrogenase in Anaerobic Phenylalanine Metabolism. *J Bacteriol* (2014) 196(2):483–92. doi: 10.1128/JB.00980-13

Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman K, et al. Bacterial Metabolites on Immune Barrier Defense Against an Intracellular Bacterial Infection Through Toll-Like Receptor 4. *Immunity* (2014) 41(2):296–310. doi: 10.1016/j.immuni.2014.06.014

Jennings JD, Mavrocons K, Mathias C, Stobart J, Blazek P, et al. Symbiotic Bacterial Metabolites Regulate Gastrointestinal Barrier Function Via the Xenobiotic Sensor PXR and Toll-Like Receptor 4. *Immunity* (2014) 41(2):296–310. doi: 10.1016/j.immuni.2014.06.014

Cervantes-Barragan L, Colonna M. AHR Signaling in the Development and Function of Intestinal Immune Cells and Beyond. *Semin Immunopathol* (2018) 40(4):371–7. doi: 10.1007/s00281-018-0699-4

Zhu J, Luo L, Tian L, Yin S, Ma X, Cheng S, et al. Aryl Hydrocarbon Receptor Promotes IL-10 Expression in Intestinal Inflammation: Insights From an Immune and Bacteria Sensor. *Clin Res Allergy Immunol* (2015) 39(3):382–90. doi: 10.1007/s12016-015-0878-9

Vlček J, Guo X, Chen Z, He L, Sonnenberg GF, Artis D, et al. Group 3 Innate Lymphoid Cells Inhibit T-cell-mediated Intestinal Inflammation Through Aryl Hydrocarbon Receptor Signaling and Regulation of Microflora. *Immunity* (2013) 39(2):386–99. doi: 10.1016/j.immuni.2013.08.002

Bock KW, Human and Rodent Aryl Hydrocarbon Receptor (AHR): From Mediator of Dioxin Toxicity to Physiologic AHR Functions and Therapeutic Dysfunctions. *Biochim Biophys Acta* - *Gene Regul Mech* (2016) 1859(9):1072–82. doi: 10.1016/j.bbagen.2016.03.012

Russell WR, Duncan SH, Scobbie L, Duncan G, Cantlay L, Calder AG, et al. Major Phenylpyruvate-Derived Metabolites in the Human Gut can Arise From Methionine by Microbiota. *Front Immunol* | www.frontiersin.org May 2021 | Volume 12 | Article 658354
Chen W, Pu A, Sheng B, Zhang Z, Li L, Liu Z, et al. Aryl Hydrocarbon Receptor Activation Modulates CD8α+ Tcrrβ+ IELs and Suppression of Colitis Manifestations in Mice. BioMed Pharmacother (2017) 87:127–34. doi: 10.1016/j.biopharma.2016.12.061

Brawner KM, Yeramilli VA, Duck LW, Van Der Pol W, Smythies LE, Morrow CD, et al. Depletion of Dietary Aryl Hydrocarbon Receptor Ligands Alters Microbiota Composition and Function. Sci Rep (2019) 9(1):1–12. doi: 10.1038/s41598-019-51194-w

Scott SA, Fu J, Chang PV. Microbial Tryptophan Metabolites Regulate Gut Barrier Function Via the Aryl Hydrocarbon Receptor. Proc Natl Acad Sci U S A (2020) 117(32):19376–87. doi: 10.1073/pnas.2000047117

Fukumoto S, Toshimitsu T, Matsuoka S, Maruyama A, Oh-Oka K, Takamura T, et al. Identification of a Probiotic Bacteria-Derived Activator of the Aryl Hydrocarbon Receptor That Inhibits Colitis. Immunol Cell Biol (2014) 92(5):460–5. doi: 10.1038/icb.2014.2

Yu K, Yang K, Zhou C, Xu P, Xiao W, Yang H. Aryl Hydrocarbon Receptor Activation Alleviates Dextran Sodium Sulfate-Induced Colitis Through Enhancing the Differentiation of Goblet Cells. Biochem Biophys Res Commun (2019) 514(1):180–6. doi: 10.1016/j.bbrc.2019.04.136

Liu Z, Li L, Chen W, Wang Q, Xiao W, Ma Y, et al. Aryl Hydrocarbon Receptor Activation Maintained the Intestinal Epithelial Barrier Function Through Notch1 Dependent Signaling Pathway. Int J Mol Med (2018) 41(3):1560–72. doi: 10.3892/ijmm.2017.3341

Yu K, Ma Y, Zhang Z, Fan X, Li T, Li L, et al. AhR Activation Protects Intestinal Epithelial Barrier Function Through Regulation of Par-6. J Mol Histol (2018) 49(5):449–58. doi: 10.1007/s10735-018-9784-1

Yu M, Wang Q, Ma Y, Li L, Yu K, Zhang Z, et al. Aryl Hydrocarbon Receptor Activation Modulates Intestinal Epithelial Barrier Function by Maintaining Tight Junction Integrity. Int J Biol Sci (2018) 14(1):69–77. doi: 10.7150/ijbs.22259

Fang L, Pang Z, Shu W, Wu W, Sun M, Cong Y, et al. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn’s Disease. Inflammation Bowel Dis (2018) 24(9):1735–44. doi: 10.1093/ibd/uyz126

Zhao Y, Ma T, Chen W, Chen Y, Li M, Ren L, et al. MicroRNA-124 Promotes the Intestinal Inflammation by Targeting AHR in Crohn’s Disease. J Crohns Colitis (2016) 10(6):703–12. doi: 10.1093/ecco-jcc/jjw010

Chng SH, Kundu P, Dominguez-Brauer C, Teo WL, Kawajiri K, Fujikuriyama Y, et al. Ablating the Aryl Hydrocarbon Receptor (AhR) in CD11c+ Cells Perturbs Intestinal Epithelium Development and Intestinal Immunity. Sci Rep (2016) 6(October 2015):2–3. doi: 10.1038/srep23820

Riemenschneider S, Hoffmann M, Slanina U, Weber K, Hauschluft S, Lehmann J. Indol-3-carbinol and Quercetin Ameliorate Chronic Dss-Induced Colitis in c57bl/6 Mice by Ahr-Mediated Anti-Inflammatory Mechanisms. Int J Environ Res Public Health (2021) 18(5):1–17. doi: 10.3390/ijerph18052262

Biagioli M, Carino A, Fiorucci C, Annunziato G, Marchiano S, Bordoni M, et al. The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions. Nutrients (2019) 11(8):1820. doi: 10.3390/nu11081820

Kamura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl Hydrocarbon Receptor in Combination With Stat1 Regulates LPS-induced Inflammatory Responses. J Exp Med (2009) 206(9):2027–35. doi: 10.1084/jem.20090560

Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in Intestinal Inflammation and Resolution: A Potential Therapeutic Target in IBD. Nat Rev Gastroenterol Hepatol (2019) 16(9):531–43. doi: 10.1038/s41575-019-0172-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Gasaly, de Vos and Hermoso. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.